The Influence of Locality on the Prevalence of Malignant Disease

Abstract

<h3>Abstract</h3> Dominant mutations in the HSP70 co-chaperone DNAJB6 cause a late onset muscle disease termed limb girdle muscular dystrophy type 1D (LGMD1D), which is characterized by protein aggregation and vacuolar myopathology. Disease mutations reside within the G/F domain of DNAJB6, but the molecular mechanisms underlying dysfunction are not well understood. Using yeast, cell culture, and mouse models of LGMD1D, we find that the toxicity associated with disease-associated DNAJB6 requires its interaction with HSP70, and that abrogating this interaction genetically or with small molecules is protective. In skeletal muscle, DNAJB6 localizes to the Z-disc with HSP70. Whereas HSP70 normally diffuses rapidly between the Z-disc and sarcoplasm, the rate of HSP70’s diffusion in LGMD1D mouse muscle is diminished likely because it has an unusual affinity for the Z-disc and mutant DNAJB6. Treating LGMD1D mice with a small molecule inhibitor of the DNAJ-HSP70 complex re-mobilizes HSP70, improves strength and corrects myopathology. These data support a model in which LGMD1D mutations in DNAJB6 are a gain-of-function disease that is, counter-intuitively, mediated via HSP70 binding. Thus, therapeutic approaches targeting HSP70:DNAJB6 may be effective in treating this inherited muscular dystrophy.